{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:49:33Z","timestamp":1768884573002,"version":"3.49.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/spegd6u9azpn","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H04235"],"award-info":[{"award-number":["21H04235"]}],"id":[{"id":"10.13039\/spegd6u9azpn","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Posaconazole is a vital drug to treat and prevent invasive fungal infections. Several factors, such as sex, body weight, total serum proteins, dietary intake, and severe mucositis, affect posaconazole pharmacokinetics (PKs). However, the relevance of other factors that affect the PKs of posaconazole in hematopoietic stem cell transplantation (HSCT) is unknown. This study explored factors influencing the PKs of posaconazole in HSCT recipients and nontransplant patients with hematological diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The authors conducted a single-institution, retrospective study. Forty-two Japanese inpatients receiving oral posaconazole tablets as prophylaxis for fungal infections were enrolled in this study. A one-compartment model with first-order absorption was used as the structural pharmacokinetic model. A population PK (PopPK) analysis was performed using a nonlinear mixed-effects modeling program, using a first-order conditional estimation method with interactions. Perl-speaks-NONMEM and R were used to evaluate the goodness of fit and visualize the output.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In 29% of the enrolled patients, the serum concentration of posaconazole was &lt;0.5 mcg\/mL, considered the effective range. PopPK analysis revealed that the patient had undergone HSCT within 1 year, diarrhea occurred more than 5 times a day, and aspartate aminotransferase were covariates that influenced apparent clearance (CL\/F). The CL\/F of posaconazole was 1.43-fold higher after HSCT and 1.26-fold higher during diarrhea.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>PopPK analysis revealed that HSCT, diarrhea, and aspartate aminotransferase were factors associated with the CL\/F of posaconazole. The trough concentration of posaconazole may be below the therapeutic range in a few patients with diarrhea and\/or after HSCT. As invasive fungal infections in patients with hematologic diseases can be life-threatening, therapeutic drug monitoring of posaconazole is strongly recommended, and patients should be carefully monitored.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001198","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T21:01:33Z","timestamp":1713819693000},"page":"611-618","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis"],"prefix":"10.1097","volume":"46","author":[{"given":"Mitsuhiro","family":"Sugimoto","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-6768","authenticated-orcid":false,"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"},{"name":"Division of Integrative Clinical Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Itohara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yamagiwa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Hanyu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisaki","family":"Mizumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"},{"name":"Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"R1-20250603","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 1","key":"R6-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2012.09.001","article-title":"Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis","volume":"40","author":"Ross","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"e01435-19","DOI":"10.1128\/AAC.01435-19","article-title":"Using state transition models to explore how the prevalence of subtherapeutic posaconazole exposures impacts the clinical utility of therapeutic drug monitoring for posaconazole tablets and oral suspension","volume":"63","author":"Lewis","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure\u2013response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20250603","first-page":"1","article-title":"Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections","volume":"8","author":"Wiederhold","year":"2016","journal-title":"Clin Pharmacol"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"e02465-17","DOI":"10.1128\/AAC.02465-17","article-title":"A population pharmacokinetic model for a solid oral tablet formulation of posaconazole","volume":"62","author":"van Iersel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"106049","DOI":"10.1016\/j.ejps.2021.106049","article-title":"Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients","volume":"168","author":"Pe\u00f1a-Lorenzo","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cmi.2022.01.029","article-title":"Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis","volume":"28","author":"Jansen","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2147\/DDDT.S384637","article-title":"A review of population pharmacokinetic models of posaconazole","volume":"16","author":"Ding","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clinbiochem.2018.01.004","article-title":"Simultaneous determination of voriconazole, posaconazole, itraconazole and hydroxy-itraconazole in human plasma using LCMS\/MS","volume":"53","author":"Jenkins","year":"2018","journal-title":"Clin Biochem"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa1104959","article-title":"Cord colitis syndrome in cord-blood stem-cell transplantation","volume":"365","author":"Herrera","year":"2011","journal-title":"N Engl J Med"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3748\/wjg.14.2262","article-title":"Endoscopic diagnosis of gastrointestinal graft-versus-host disease","volume":"14","author":"Xu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00228-016-2057-6","article-title":"Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients","volume":"72","author":"Vanstraelen","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40261-019-00833-1","article-title":"Pharmacokinetics and safety of posaconazole administered by intravenous solution and oral tablet in healthy Chinese subjects and effect of food on tablet bioavailability","volume":"39","author":"Li","year":"2019","journal-title":"Clin Drug Investig"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/myc.12339","article-title":"Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis","volume":"58","author":"Miceli","year":"2015","journal-title":"Mycoses"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jac\/dkz546","article-title":"Implications for IV posaconazole dosing in the era of obesity","volume":"75","author":"Wasmann","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00228-012-1212-y","article-title":"Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"68","author":"Vehreschild","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"e02230-17","DOI":"10.1128\/AAC.02230-17","article-title":"The genetic polymorphism UGT1A4*3 is associated with low posaconazole plasma concentrations in hematological malignancy patients receiving the oral suspension","volume":"62","author":"Suh","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:10:41Z","timestamp":1748970641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001198","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"2023-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}